SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently a focal point for intense debate after a high-profile endorsement from Donald Trump triggered extreme volatility, even as bearish analysts like Michael Burry continue to target the stock over valuation concerns and competitive threats. The community remains deeply divided, with bulls pointing to the company's deepening entrenchment in critical government defense contracts, while bears question the sustainability of its premium valuation and the impact of evolving AI landscape competition.

Maulcoin

Maulcoin is trending as a community-driven movement that is gaining significant social traction and investor interest through persistent organic growth and active promotion across multiple platforms. Enthusiasts are currently focused on maintaining momentum, resisting profit-taking, and pushing the project toward higher market capitalization targets while anticipating upcoming technical developments and listing milestones.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending as it joins the Nasdaq-100, fueling intense community debate over whether the stock's massive year-to-date rally is a sustainable AI-driven growth story or an overextended bubble nearing a blow-off top. Traders are actively analyzing the impact of forced institutional buying against extreme options flow and technical indicators, with sentiment split between those expecting a continued parabolic run to four digits and those bracing for a sharp reversal.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently capturing significant investor attention as the community debates its potential to disrupt the photonics sector through its proprietary electro-optic polymer technology. Fueled by recent foundry integration news and speculation regarding high-profile partnerships, the stock is experiencing high volatility as traders weigh long-term growth prospects against concerns over pre-revenue status and short-term market speculation.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending as the community scrutinizes recent management turnover, reverse stock splits, and ongoing leadership controversies, despite the company's focus on its late-stage psychiatry pipeline anchored by its lead program, DT120. While some investors remain bullish on the long-term potential for lysergide tartrate as a mental health breakthrough, others are vocal about concerns regarding cash burn, dilution, and the company's history of corporate governance issues.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is driving intense community engagement through its 'permissionless brand' model, which encourages holders to launch tangible real-world initiatives like energy drinks and apparel. Investors are consistently showcasing their long-term conviction by highlighting these daily IRL efforts and widespread grassroots activity as the primary catalyst for the project's growth.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market activity and social media buzz driven by speculation around high-profile partnerships, upcoming festival events, and its role in a decentralized music-event ecosystem. The community is sharply divided, with enthusiasts highlighting aggressive accumulation and technical breakout potential, while critics dismiss the asset as a volatile pump-and-dump scheme.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is seeing intense investor focus as the market closely monitors the company's progress on scaling its AI and high-performance computing infrastructure, with many traders betting on potential contract announcements for its Kentucky site. The community is actively debating the company's execution capabilities versus its competitors, while heavy short interest continues to fuel speculation about a possible short squeeze if the stock sustains its recent upward momentum.

WorldFinancial

WorldFinancial (WLFI) is experiencing intense community debate, with bulls citing a potential short squeeze, strategic institutional partnerships, and the upcoming Mar-a-Lago forum as major catalysts for a price rebound. Conversely, bears are dismissing the asset as a speculative pump-and-dump scheme, pointing to regulatory scrutiny and skepticism regarding management's transparency as primary risks.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. (OGN) is seeing intense trading activity driven by unconfirmed market rumors of a multi-billion dollar buyout offer from Sun Pharma. While the stock has experienced significant volatility and heavy volume as traders debate the credibility of these reports, the community remains divided between those betting on an M&A catalyst and those concerned about the company's substantial debt load.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities...

JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

JPMorgan Chase & Co. cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,302,498 shares of the company's stock after sell...

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Truist Financial

Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday. They set a "buy" rating and a $57.00 price target on the stock...

NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC's 5th Largest Position

Decheng Capital LLC trimmed its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with...

ArrowMark Colorado Holdings LLC Has $8.85 Million Holdings in NewAmsterdam Pharma Company N.V. $NAMS

ArrowMark Colorado Holdings LLC reduced its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 13.3% in the 3rd quarter, according to the company in its most recent...

NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $1,357,309.98 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director Louis Lange sold 44,619 shares of the business's stock in a transaction on Wednesday, March 11th. The stock was sold at an...

NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc.

American Century Companies Inc. lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 17.1% in the 3rd quarter, according to its most recent disclosure with...

Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director Louis Lange sold 28,186 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average...

Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 94,124 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 94,124 shares of the company's stock in a transaction on Friday, March 6th. The shares...

Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 104,467 shares of the firm's stock in a transaction on Thursday, March 5th. The stock was...

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

NAMS
NewAmsterdam Pharma Company NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NAMS News

NAMSNewAmsterdam Pharma Company NV